FDA, CDC experts: What physicians need to know about tecovirimat (TPOXX) for treatment of monkeypox, Part 2

Experts from the FDA and CDC continue their discussion on tecovirimat, or TPOXX, for the treatment of monkeypox in infected individuals. In part two of this mini-series, experts answer physicians' questions about treatment for monkeypox. Guests include Adam Sherwat, MD, Deputy Director, Office of Infectious Disease at FDA’s Center for Drug Evaluation and Research; Brett W. Petersen, MD, MPH, Deputy Chief, Poxvirus and Rabies Branch, CDC’s Division of High-Consequence Pathogens and Pathology; and Timothy Wilkin, MD, MPH, Professor of Medicine and Assistant Dean for Clinical Research Compliance for Human Research Protections at Weill Cornell Medicine and TPOXX clinical trial lead.

⭐⭐⭐⭐⭐

🩺 The AMA is your powerful ally, focused on addressing the issues
important to you, so you can focus on what matters most — patients. We
will meet this challenge together. Join us:
https://ama-assn.co/JoinRenew

🥼 Go to https://ama-assn.co/FightingForDocs to learn more about our AMA
advocacy priorities, including:

▹ Reforming Medicare payment 
▹ Fighting scope creep 
▹ Fixing prior authorization 
▹ Reducing physician burnout 
▹ Making technology work for physicians

📺 Subscribe to @americanmedicalassociation on YouTube:
https://ama-assn.co/youTube

📧 Sign up for #MorningRounds and free daily newsletters from the AMA:
https://ama-assn.co/Newsletters

💬 Follow #AMA on social media: https://ama-assn.co/Social